source
- STAT+: NIAID acting head John Powers III appointed as the permanent directorThe acting director of NIAID, John Powers III, will become the permanent director, the agency announced Monday.STAT · 41m ago↗ source
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drugThe FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.BioPharma Dive · 1h ago↗ source
- CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trialCG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.BioPharma Dive · 1h ago↗ source